InsiderTrades

Form 4 for IDXX Idexx Laboratories

Accepted 2023-02-13 00:00:00 ET · period of report 2023-02-09 · accession 0001567619-23-002572 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2023-02-13 2023-02-09 IDXX Turner Kathy V SVP M - OptEx $79.54 +1,000 7,941 +14% +$79.5K
D 2023-02-13 2023-02-09 IDXX Turner Kathy V SVP S - Sale+OE $505.04 -1,000 6,941 -13% -$505.0K
D 2023-02-13 2023-02-09 IDXX Turner Kathy V SVP M - OptEx — -1,000 6,736 -13% —

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2023-02-09 M A 1,000 $79.54 7,940.85 D — — (F1) Includes 17.4623 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on December 31, 2022.
2 Common Common Stock 2023-02-09 S D 1,000 $505.04 6,940.85 D — — (F2) Represents the weighted average price of the shares sold ranging from a low of $505.00 to a high of $505.19 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
3 Derivative Non-Qualified Stock Option (right-to-buy) 2023-02-09 M D 1,000 — 6,736 D $79.54 · — to 2025-02-13 1,000 Common Stock (F5) Not applicable. (F4) Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,993 shares in five annual installments beginning February 15, 2016, without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.